Contraindications by Peptide Class

"Is this peptide safe?" is the wrong question. The right one is: is this peptide safe for me, given what I already have going on?

A healing peptide that's benign for a twenty-five-year-old athlete can be a poor choice for someone with an active malignancy. A GLP-1 that's a straightforward tool for most is contraindicated in specific thyroid conditions. The peptide hasn't changed — the context has.

This is the class-by-class rundown of who should probably not run these compounds, or should at minimum not run them without clinical supervision.

GH secretagogues (sermorelin, ipamorelin, CJC-1295, tesamorelin, hexarelin, MK-677)

These push endogenous growth hormone release, which means they indirectly elevate IGF-1. IGF-1 is a growth factor. Growth factors feed tissue that's growing — including tissue you don't want growing.

Hard contraindications:

• Active malignancy. Any current cancer diagnosis. The IGF-1 axis is implicated in tumor growth across multiple cancer types.
• History of certain cancers within the last 5 years. Breast, colon, prostate especially. Discuss with an oncologist before considering.
• Active proliferative diabetic retinopathy. GH/IGF-1 worsens it.
• Pregnancy or breastfeeding. No safety data; risk unjustified.

Proceed only with clinical supervision:

• Poorly controlled type 2 diabetes. GH antagonizes insulin; glucose will drift upward.
• Acromegaly or pituitary tumors. Obviously.
• Severe sleep apnea. GH can worsen fluid retention and airway soft tissue.
• Carpal tunnel syndrome. Fluid retention from GH makes this worse.

Caution:

• Family history of cancer with a strong IGF-1 link. Not an absolute no, but worth a conversation with a clinician and close monitoring.
• Existing high IGF-1. Check a baseline. If you're already at the top of the reference range, adding more is not the move.

GLP-1 and dual/triple agonists (semaglutide, tirzepatide, retatrutide, liraglutide)

These are increasingly well-studied, and the contraindication list is relatively well-defined because of prescription drug labeling.

Hard contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC). Black-box warning on semaglutide and related compounds.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Same thyroid tumor risk.
• History of pancreatitis. GLP-1s have a well-documented pancreatitis signal. If you've had it once, you're at higher risk of having it again.
• Severe gastroparesis. GLP-1s slow gastric emptying — this makes gastroparesis significantly worse.
• Pregnancy. Animal studies show fetal harm. Manufacturers recommend discontinuation two months before conception.

Proceed only with clinical supervision:

• Type 1 diabetes. GLP-1s are not approved for T1; DKA risk without careful monitoring.
• Severe gallbladder disease or recent cholecystectomy. Gallbladder events are elevated on GLP-1s.
• Eating disorder history (anorexia, bulimia). The appetite-suppression mechanism is a hazard here.
• Severe renal impairment. Dehydration from GI side effects worsens kidney function.

Caution:

• Planning to become pregnant. Discontinue before trying to conceive.
• Low baseline BMI. These aren't cosmetic tools for already-lean people; the risk/benefit gets worse as BMI drops.

IGF-1 analogs (IGF-1 LR3, IGF-1 DES)

All the GH-secretagogue cancer and retinopathy contraindications apply, but more directly — you're administering the growth factor itself rather than stimulating its release.

Hard contraindications:

• Any current or recent cancer diagnosis. Stronger than the GH-secretagogue case.
• Active proliferative retinopathy.
• Pregnancy or breastfeeding.
• Severe hypoglycemia risk (insulin-dependent diabetes without careful monitoring). IGF-1 has insulin-like effects.

Proceed only with clinical supervision:

• Any history of cancer. Not just recent.
• Diabetes of any type. Glucose handling will shift unpredictably.
• Significant cardiovascular disease. Left ventricular hypertrophy is a theoretical concern on chronic dosing.

This class has a narrower risk/benefit window than GH secretagogues. Many users who would be fine on sermorelin should not be on IGF-1 LR3.

Melanocortin peptides (PT-141 / bremelanotide, melanotan II)

Act on melanocortin receptors — cardiovascular and pigmentation effects are baked in.

Hard contraindications:

• Uncontrolled hypertension. PT-141 transiently raises blood pressure.
• Recent cardiovascular event (MI, stroke, unstable angina).
• History of melanoma. Melanotan II especially — you're stimulating melanocytes.

Proceed only with clinical supervision:

• Existing cardiovascular disease.
• Atypical moles / high melanoma risk. Melanotan II in particular; PT-141 less so but caution is reasonable.
• Pregnancy. Insufficient data.

Healing peptides (BPC-157, TB-500 / thymosin beta-4, GHK-Cu)

Lowest-risk class overall, but still not zero.

Hard contraindications:

• Active malignancy. BPC-157 and TB-500 are angiogenic — they promote new blood vessel growth. Tumors use angiogenesis. This is theoretical more than documented, but the risk/benefit doesn't justify use during active cancer.
• Pregnancy. No safety data.

Proceed only with clinical supervision:

• History of cancer within the last 5 years.
• Known proliferative conditions (polyps, fibroids that are being monitored for growth).

For BPC-157 specifically the real-world safety profile in the community is remarkably clean, but the angiogenesis concern is why the standard community advice is "not during active cancer treatment."

Thymic peptides (thymosin alpha-1, thymulin)

Immune modulators.

Hard contraindications:

• Active autoimmune disease on flare (lupus, MS, RA in active phase). These compounds shift immune tone; unpredictable effects in active autoimmunity.
• Immunosuppression for organ transplant. Counter to the transplant regimen's purpose.

Cognitive peptides (semax, selank, cerebrolysin, dihexa)

Variable profiles; the data is thinner than for other classes.

Proceed only with clinical supervision:

• Seizure disorders. Effects on neural excitability are not fully characterized.
• Bipolar disorder. Mood shifts reported, not always in the direction hoped for.
• On SSRIs, MAOIs, or other serotonergic agents. See drug interactions.

Universal cautions

Some contraindications cross every class:

• Pregnancy and breastfeeding. Default to no peptides. The safety data doesn't exist.
• Age under 18. Endocrine systems are still developing. Don't.
• Active, unexplained, or untreated medical conditions. Find out what's going on first.
• On multiple chronic medications without clinician oversight. Interactions multiply.

When to stop and see a doctor

If you're on a peptide and any of the contraindications above apply to you — and you didn't realize it when starting — stop the protocol. Schedule a visit with a clinician who knows about peptides (increasingly, this is realistic) or bring the compound name and mechanism to your regular provider. "I've been taking this, here's what it does, here's my history" is a conversation most physicians can work with. Hiding what you're doing is how bad outcomes happen.

Where to go next

• Drug interactions to know about covers medications that specifically interact with common peptides.
• Red flags: when to stop a protocol immediately is the symptom/lab list for mid-cycle warning signs.
• Cycling principles covers how to structure protocols to minimize long-term risk.

---

This is educational content, not medical advice. Abnormal labs or symptoms warrant consultation with a qualified healthcare provider.